Valeant Pharmaceuticals International, Inc. has announced new fulfillment agreements with Walgreens. In conjunction with this deal, Valeant will reduce the wholesale list prices of its branded prescription-based dermatological and ophthalmological products by 10 per cent over the next six to nine months.
This model is designed to help reduce costs and administrative processes, yielding savings that can benefit both patients and the healthcare system. The agreement will enable consumers to conveniently access Valeant’s products at a lower out-of-pocket cost from more than 8,000 Walgreens U.S. retail pharmacy locations, as well as participating independent retailers.
Through this, the company aims to create a more efficient model to help lower costs while ensuring patients have convenient access to the products their doctors prescribe. Patients with commercial insurance can benefit from lower out-of-pocket costs, such as reduced copays, and the program will provide convenient access for patients who lack coverage for the products. (Zolpidem) However, due to government regulation, the cost-sharing program will not be applicable to patients with government insurance.
“We have listened to what the marketplace is saying and we’ve taken positive steps to respond,” says J. Michael Pearson, chairman and CEO of Valeant. “Our goal is to create a system that allows prescription medications to be dispensed and insurance claims adjudicated in an efficient manner while allowing physicians to focus their efforts on what matters most: patient care.”
